CapsoVision, Inc. Common Stock logo

CapsoVision, Inc. Common Stock(CV)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
SELL
SELL for 3 days
PROFIT SINCE LAST BUY
-7.79% ▼
LAST CLOSE
$6.03
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CV

11/13/2026: CV (1-star) is a SELL. SELL for 3 days. Simulated Profits (-7.79%). Updated daily EoD!

CapsoVision is a commercial-stage medical technology company specializing in gastrointestinal diagnostic imaging solutions like the CapsoCam Plus capsule endoscope. Its primary business strengths lie in its unique 360-degree panoramic camera design and recent integrations of AI-driven diagnostic highlight features. The main investment story centers on expanding hospital adoption and software utilization in the non-invasive small-bowel screening market. However, the company faces notable execution risks, ongoing net operating losses, and intense competition from dominant industry incumbents like Medtronic. The stock suits growth-oriented investors with a high risk tolerance willing to monitor clinical adoption milestones and cash burn trends.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile operating in an innovative medical device niche with expanding revenues, its small scale introduces higher execution uncertainty.
Momentum investorStrong fit while signal remains positiveShort-term momentum can spike around regulatory approvals and clinical data updates, subject to an active upturn signal.
Value investorWeak fitThe company lacks current profitability and positive earnings, making traditional value metrics unsupportable.
Dividend investorWeak fitCapsoVision does not pay dividends and retains all capital for business expansion.
Low-risk investorWeak fitHigh share price volatility and ongoing net losses create elevated risk exposure for conservative capital.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences significant price swings characteristic of small-cap commercial-stage medical device equities.
Valuation riskMedium / highValuation relies heavily on long-term future adoption expectations rather than current earnings power.
Competition risk (Medtronic and major medtech)HighWell-funded competitors possess superior marketing resources and entrenched hospital distribution channels.
Business qualityMediumProprietary medical technology provides an operational niche, but financial self-sustainability is still under development.
Dividend incomeLow / noneNo cash distributions or dividends are paid to shareholders.
Execution riskHighCommercial success depends heavily on expanding physician adoption and navigating complex medical reimbursement structures.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 323.27M USD
Price to earnings Ratio -
1Y Target Price 9.5
Price to earnings Ratio -
1Y Target Price 9.5
Volume (30-day avg) 119.5K shares
Beta -
52 Weeks Range 4.50 - 15.37
Updated Date 11/15/2026
52 Weeks Range 4.50 - 15.37
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.42

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steady Uptrend
PRICE PATH

Steady Uptrend

The stock demonstrates consistent and steady upward price momentum.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit 46.24%
Avg. Invested days 27
Today’s Advisory SELL
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CV receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
CV has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, solid revenue growth (+15.3%) is partially offset by negative earnings growth (-27.2%), weak cash generation (FCF margin -169.4%), weak profitability (net margin -186.8%).

Financial Health Rating

★★★★★
CV's financial health is soft, with the relatively strongest area being solid liquidity, including working-capital and asset support (WC/assets 67.4%). Operating efficiency is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is CV's strongest growth driver at +15.3% FY2025 versus FY2024 (solid, 4 stars). By comparison, while earnings growth (-27.2%, negative) and free-cash-flow growth (-13.4%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 12.0% and approximately 55.9% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 33.72% supports management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 4.05%
Vanguard Capital Management, LLC 2.26%
Geode Capital Management, LLC 1.23%
State Street Corp 0.88%
Vanguard Portfolio Management, LLC 0.51%

Unit Economics (Per $1K Revenue)

★★★★★
CV generates approximately $529 of gross profit, $-1,883 of operating income, and $-1,694 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 2-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.09% (Tax Credit)

Quantitative Style Profile

★★★★★
CV has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Capsule Endoscopy Hardware SalesRevenues generated from the sale of single-use CapsoCam Plus capsules to clinics, hospitals, and medical distributors.This is the core physical product engine driving daily device utilization.
Software and Ancillary SolutionsLicensing and utilization fees associated with CapsoView and CapsoCloud diagnostic software platforms.Software offerings provide recurring touchpoints and workflow integration for clinical users.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 302.29M
Price to Sales(TTM) 23.22
Enterprise Value 302.29M
Price to Sales(TTM) 23.22
Enterprise Value to Revenue 21.71
Enterprise Value to EBITDA -
Shares Outstanding 53.61M
Shares Floating 29.97M
Shares Outstanding 53.61M
Shares Floating 29.97M
Percent Insiders 33.72
Percent Institutions 11.96

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.